Cross-Titration from Olanzapine to Quetiapine

Rationale and Protocol

The American Academy of Family Physicians recommends starting quetiapine at 25mg twice daily while maintaining olanzapine 10mg daily, then tapering olanzapine by 2.5-5mg every 3-7 days while simultaneously increasing quetiapine to a target dose of 300-400mg/day over 1-2 weeks, to minimize risk of symptom exacerbation 1, 2, 3
The cross-titration strategy is preferred over abrupt switching due to the patient's complex symptom profile, including anxiety, agitation, bipolar mood, and sleep disturbances, as it allows for a more gradual transition and reduces the risk of rebound symptoms 1, 2, 3

Orthostatic vital signs should be checked before each dose adjustment, as quetiapine causes more sedation and transient orthostasis than olanzapine, with a particular focus on monitoring blood pressure sitting and standing, especially during the first 2 weeks 1, 3, 5
Sleep quality is expected to improve as quetiapine dose increases due to its sedating properties, and should be monitored regularly 1, 5
Metabolic parameters, including weight, glucose, and lipids, should be monitored at baseline and follow-up, as both olanzapine and quetiapine can cause metabolic effects, although olanzapine has a higher risk for weight gain and dyslipidemia 1, 3

Quetiapine is significantly more sedating than olanzapine, and a dosing strategy that gives a larger portion of the quetiapine dose at bedtime can help leverage sedation for sleep while minimizing daytime somnolence 1, 3, 5
The final quetiapine dose should typically be 300-400mg/day for bipolar disorder and agitation, although the effective range is 150-750mg/day, and asymmetric dosing with the larger portion at bedtime may be considered for patients with sleep disturbances 1, 3, 4

For elderly or frail patients, quetiapine should be started at 12.5mg twice daily instead of 25mg twice daily, and olanzapine should be reduced more gradually, with a focus on minimizing the risk of adverse effects 1, 3
In patients with hepatic impairment, lower starting doses of quetiapine and slower titration are recommended, with a focus on minimizing the risk of adverse effects and ensuring safe use 1, 3